empty

Financial Management & Funding

123 results found for: Financial Management & Funding

Counting the cost of Covid-19

Two months into Covid-19, and community pharmacies have been counting the costs of dealing with the pandemic. 

Covid-19: property questions addressed

Solicitors Michelle Noble and Aidan Welton consider the options available to pharmacists in respect of property costs during the pandemic.

SMEs encouraged to invest in innovation

Tax preparation specialist David Redfern reviews HMRC's Advance Assurance R&D tax relief scheme for small and medium sized companies

Numbers crunched for 2019

IQVIA's Carol Alexandre crunched the numbers from 2019 on pharmacies, distributors, generics and DSPs at this year's Sigma Conference 

No respite in challenges for the generics sector

Medicines supply is never out of the news. What do those in the generics sector see as the prospects for 2020?

Held to account

Time and money are the biggest squeezes on most businesses. Engaging a specialist accountant is an investment to consider

Business ambition in action

We catch up with two of our Planning for Growth business development participants, to find out how they're getting on, four months in

Planning to grow: five pharmacies sign in

P3pharmacy has teamed up with Pharmacy Complete to follow five independent pharmacy owners through a structured business development programme over the course of a year. 

Five more local ways to up your game

Part three of Real World Analytics' Conall Lavery's rundown of 20 ways to use data to improve business performance. This month: items 11-15 

Hammond: Spending boost if Brexit deal passes

A £26.6bn fund set aside for a no-deal Brexit will go towards boosting public spending if the UK leaves with a deal

Put patient panic to rest

Brexit has got patients worried about their medicines supply. Here's what to tell them

Can you see it coming?

Conall Lavery of Real World Analytics says the more information you have, the better the chance of success you will have in managing the NHS funding cuts. 

Drug Tariff distribution changes

NHS England is to stop automatically sending monthly printed copies to community pharmacies after January

CMA drops generics pricing investigation

The Competition and Markets Authority concluded that the case was not a good use of its resources

Industry & govt near agreement on PPRS successor

The NHS across the UK is expected to save around £930m on its medicine bill under a new scheme

Pharmacists linked to care homes as part of £3.5bn investment

Pharmacists and GPs are to be assigned to care homes in a measure Theresa May says will be "better for patients"

Making Tax Digital: time to prepare

By the end of March 2019, UK businesses will need to be prepared for an HMRC change which will affect every single transaction a business makes. Welcome to Making Tax Digital (MTD)

NI pharmacy “light years behind”, facing “indiscriminate” closures

The funding crisis facing the community pharmacy sector in Northern Ireland will cause widespread closures, CPNI has said

'Rise in complaints' partly behind GPhC fee proposals

A “rising number of concerns about registrants” being raised is among the workload factors that have contributed to the GPhC's proposing to increase its fees

Most expensive NHS drug comes off patent

Adalimumab (Humira; AbbVie) is a biological medicine used to treat conditions including rheumatoid arthritis and Crohn’s disease

Previous 1 2 3 4 5 6 7 Next


This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to P3 Pharmacy's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.